Business Description
Gan and Lee Pharmaceuticals
ISIN : CNE100003ZH1
Share Class Description:
SHSE:603087: Class ATotal Employee Number:
5,309Compare
Compare
Traded in other countries / regions
603087.China Index Membership
SSE Composite IndexCSI 500 IndexCSI 300 Index IPO Date
2020-06-29Description
Gan and Lee Pharmaceuticals is engaged in Research, development, production and sales of recombinant insulin analog APIs and injections.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 329.5 | |||||
Equity-to-Asset | 0.92 | |||||
Debt-to-EBITDA | 0.01 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 24.51 | |||||
Beneish M-Score | -2.03 | |||||
WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 31 | |||||
3-Year FCF Growth Rate | 41.9 | |||||
3-Year Book Growth Rate | 4.7 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 19.94 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 18.13 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 24.29 | |||||
9-Day RSI | 36.25 | |||||
14-Day RSI | 42.54 | |||||
3-1 Month Momentum % | 33.43 | |||||
6-1 Month Momentum % | 17.29 | |||||
12-1 Month Momentum % | 0.05 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 6.91 | |||||
Quick Ratio | 5.67 | |||||
Cash Ratio | 4.12 | |||||
Days Inventory | 370.42 | |||||
Days Sales Outstanding | 48.44 | |||||
Days Payable | 49.14 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 1.47 | |||||
Dividend Payout Ratio | 0.51 | |||||
3-Year Dividend Growth Rate | 49.4 | |||||
Forward Dividend Yield % | 1.47 | |||||
5-Year Yield-on-Cost % | 1.47 | |||||
3-Year Average Share Buyback Ratio | -1.8 | |||||
Shareholder Yield % | 1.47 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 74.73 | |||||
Operating Margin % | 21.78 | |||||
Net Margin % | 27.32 | |||||
EBITDA Margin % | 29.14 | |||||
FCF Margin % | -2.82 | |||||
OCF Margin % | 23 | |||||
ROE % | 10.01 | |||||
ROA % | 9.26 | |||||
ROIC % | 10.01 | |||||
3-Year ROIIC % | 38.03 | |||||
ROC (Joel Greenblatt) % | 25.24 | |||||
ROCE % | 10.51 | |||||
Years of Profitability over Past 10-Year | 9 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 34.2 | |||||
Forward PE Ratio | 24.15 | |||||
PE Ratio without NRI | 33.62 | |||||
Shiller PE Ratio | 40.58 | |||||
Price-to-Owner-Earnings | 81 | |||||
PS Ratio | 9.36 | |||||
PB Ratio | 3.38 | |||||
Price-to-Tangible-Book | 4.2 | |||||
Price-to-Operating-Cash-Flow | 40.67 | |||||
EV-to-EBIT | 30.21 | |||||
EV-to-EBITDA | 30.21 | |||||
EV-to-Revenue | 8.8 | |||||
EV-to-FCF | -312.02 | |||||
Price-to-GF-Value | 0.91 | |||||
Price-to-Projected-FCF | 4.56 | |||||
Price-to-Graham-Number | 2.51 | |||||
| Price-to-Net-Current-Asset-Value | 8.18 | |||||
| Price-to-Net-Cash | 16.06 | |||||
Earnings Yield (Greenblatt) % | 3.31 | |||||
FCF Yield % | -0.3 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
Gan and Lee Pharmaceuticals Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 4,208.373 | ||
| EPS (TTM) (¥) | 1.94 | ||
| Beta | 1.1424 | ||
| 3-Year Sharpe Ratio | 0.49 | ||
| 3-Year Sortino Ratio | 0.83 | ||
| Volatility % | 31.36 | ||
| 14-Day RSI | 42.54 | ||
| 14-Day ATR (¥) | 2.586938 | ||
| 20-Day SMA (¥) | 69.92 | ||
| 12-1 Month Momentum % | 0.05 | ||
| 52-Week Range (¥) | 51.51 - 82.25 | ||
| Shares Outstanding (Mil) | 597.43 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Gan and Lee Pharmaceuticals Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Gan and Lee Pharmaceuticals Stock Events
| Event | Date | Price (¥) | ||
|---|---|---|---|---|
| CNY 1.000000 Cash Dividend | 2026-05-29 | 53.05 (-0.36%) | ||
| CNY 1.000000 Cash Dividend | 2025-06-11 | 58.72 (+3.20%) | ||
| CNY 0.500000 Cash Dividend | 2024-12-02 | 46.59 (+2.31%) | ||
| 1.4:1 Stock Split | 2020-08-20 | 149.41 (-1.33%) |
Show
Entries
Gan and Lee Pharmaceuticals Frequently Asked Questions
What is Gan and Lee Pharmaceuticals(SHSE:603087)'s stock price today?
The current price of SHSE:603087 is ¥66.34. The 52 week high of SHSE:603087 is ¥82.25 and 52 week low is ¥51.51.
When is next earnings date of Gan and Lee Pharmaceuticals(SHSE:603087)?
The next earnings date of Gan and Lee Pharmaceuticals(SHSE:603087) is .
Does Gan and Lee Pharmaceuticals(SHSE:603087) pay dividends? If so, how much?
The Dividend Yield % of Gan and Lee Pharmaceuticals(SHSE:603087) is 1.47% (As of Today), Highest Dividend Payout Ratio of Gan and Lee Pharmaceuticals(SHSE:603087) was 0.96. The lowest was 0.16. And the median was 0.46. The Forward Dividend Yield % of Gan and Lee Pharmaceuticals(SHSE:603087) is 1.47%. For more information regarding to dividend, please check our Dividend Page.
Press Release
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers